Physicochemical Properties of Glimepiride in Solid Dispersions with Polyethylene Glycol 20000

DOI:

https://doi.org/10.37285/ijpsn.2009.2.2.7

Authors

  • O.P. Baliar Singh
  • S. Biswal
  • J. Sahoo
  • P. N. Murthy

Abstract

The aim of this study was to investigate the physicochemical properties of glimepiride in SDs with PEG 20000. The phase solubility behavior of glimepiride in presence of various concentrations of PEG 20000 in pH 7.4 buffer was obtained at 37oC. The solubility of glimepiride increased with increasing amount of PEG 20000 in pH 7.4 buffer. Gibbs free energy (ΔGotr) values were all negative, indicating the spontaneous nature of glimepiride solubilization and ΔGotr decreased with increase in the PEG 20000 concentration, demonstrating that the reaction conditions became more favorable as the concentration of PEG 20000 increased. The SDs of glimepiride with PEG 20000 were prepared at 1:1, 1:3 and 1:5 (glimepiride: PEG 20000) ratio by melting method. Evaluation of the properties of the SDs was performed by using dissolution, Fourier-transform infrared (FTIR) spectroscopy and X-ray diffraction (XRD) studies. The SDs of glimepiride with PEG 20000 exhibited enhanced dissolution rate of glimepiride, and the rate increased with increasing concentration of PEG 20000 in SDs. Mean dissolution time (MDT) of glimepiride decreased significantly after preparation of SDs and physical mixture with PEG 20000. The FTIR spectroscopic studies showed the stability of glimepiride and absence of well-defined glimepiride-PEG 20000 interaction. The XRD studies indicated the amorphous state of glimepiride in SDs of glimepiride with PEG 20000.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Glimepiride, Solid dispersion, PEG 20000, Dissolution, Solubility

Downloads

Published

2009-08-31

How to Cite

1.
Singh OB, S. Biswal, J. Sahoo, Murthy PN. Physicochemical Properties of Glimepiride in Solid Dispersions with Polyethylene Glycol 20000. Scopus Indexed [Internet]. 2009 Aug. 31 [cited 2024 Nov. 19];2(2):537-43. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/460

Issue

Vol. 2 No. 2 (2009): July-September 2009

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Ammara HO, Salama HA, Ghorab M and Mahmouda AA. Formulation and biological evaluation of glimepiride–cyclodextrin–polymer systems. Int. J. Pharm.309: 129–138 (2006a).

Ammara HO, Salama HA, Ghorab M and Mahmouda AA. Formulation and. Implication of inclusion complexation of glimepiride in cyclodextrin–polymer systems on its dissolution, stability and therapeutic efficacy. Int. J. Pharm. 320: 53–57 (2006b).

Anguiana-Igea S, Otero-Espinar FJ, Vila-Jato JL and Blanco-Mendez J. The properties of solid dispersions of clofibrate in polyethylene glycol. Pharm. Act Helv. 70: 57-66 (1995).

Arias MJ, Gines JM, Moyano JR and Rabasco AM. Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols. Pharm. Acta Helv. 71: 229–235 (1996).

Betageri GV and Makarla KR. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int. J. Pharm. 126:155-160 (1995).

Ford JL. The current status of solid dispersions. Pharm. Acta Helv. 61:69-88 (1986).

Frick A, Moller H, and Wirbitzki E. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. Eur. J. Pharm. Biopharm. 46: 305–311 (1998).

Geinsen K. Special pharmacology of the new sulfonylurea glimepiride. Drug Res. 38: 1120–1130 (1988).

Greenwald R.B. PEG drugs: an overview. J. Cont. Rel. 74: 159-171 (2001).

Higuchi T and Connors K. Phase solubility techniques. Adv. in Ana. Chem. and Instrument. 4:17–123 (1965).

Khan CA and Rhodes CT. The concept of dissolution efficiency. J. Pharm. Pharmacol. 27: 48–49 (1975).

Kouichi I, Masaki W, Youhei N, Takahiro S, Nobuki T, Masahiko T, Hideyuki K, Kensuke Y, Masao S, Susumu K, Takuya A, and Shigehiro K. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diab. Res. Clin. Pract. 68: 250-257 (2005).

Leuner C and Dressman J. Improving drug solubility for oral delivery using solid dispersion. Eur. J. Pharm. Biopharm. 50: 47-60 (2000).

Lobenberg R and Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system: new scientific approaches to international regulatory standards. Eur. J. Pharm. and Biopharm. 50: 3-12 (2000).

Massimo MB. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin. Ther. 25: 799–816 (2003).

Mooter GV, Augustijns P, Blaton N and Kinget R. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int. J. Pharm.164: 67–80 (1998).

Muller G, Wied S, Wetekam E, Crecelius A, and Unkelbach A. Stimulation of glucose utilization in 3P3 adipocytes and rat diaphragm in vitro by the sulfonylureas glimepiride and glibenclamide is correlated with modulations of the cAMP regulatory cascade. Biochem. Pharmacol. 48: 985–996 (1994).

Trapani G, Franco M, Latrofa A, Tullio C, Provenzano MR, Serra M, Muggironi M, Biggio G, and Liso G. Dissolution properties and anticonvulsant activity of phenytoin- polyethylene glycol 6000 and-polyvinylpyrrolidone K-30 solid dispersions. Int. J. Pharm. 225: 63–73 (2001).

Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, and Lobenberg R. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, Lactose, Sorbitol, Dextrin, and Eudragit E100. Drug Dev. and Ind. Pharm. 30 (3):303–317 (2004).

Winters S, York P, and Timmins P. Solid state examination of a gliclazide: beta-cyclodextrin complex. Eur. J. Pharma. Sc. 5:209–214 (1997).